0001209191-17-035186.txt : 20170524 0001209191-17-035186.hdr.sgml : 20170524 20170524211324 ACCESSION NUMBER: 0001209191-17-035186 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20170522 FILED AS OF DATE: 20170524 DATE AS OF CHANGE: 20170524 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Revance Therapeutics, Inc. CENTRAL INDEX KEY: 0001479290 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 770551645 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 7555 GATEWAY BLVD. CITY: NEWARK STATE: CA ZIP: 94560 BUSINESS PHONE: 510-742-3400 MAIL ADDRESS: STREET 1: 7555 GATEWAY BLVD. CITY: NEWARK STATE: CA ZIP: 94560 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Browne L Daniel CENTRAL INDEX KEY: 0001597583 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36297 FILM NUMBER: 17868089 MAIL ADDRESS: STREET 1: 7555 GATEWAY BOULEVARD CITY: NEWARK STATE: CA ZIP: 94560 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2017-05-22 0 0001479290 Revance Therapeutics, Inc. RVNC 0001597583 Browne L Daniel C/O REVANCE THERAPEUTICS, INC. 7555 GATEWAY BOULEVARD NEWARK CA 94560 1 1 0 0 CEO and President Common Stock 2017-05-22 4 S 0 12287 20.1969 D 183932 D Common Stock 2017-05-24 4 S 0 19713 20.3465 D 164219 D Common Stock 409 I See footnote The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by Mr. Browne. The shares were disposed to satisfy tax withholding obligations that arose in connection with the vesting of 32,000 shares of restricted stock on May 19, 2017. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.99 to $20.20. Mr. Browne undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.20 to $20.65. Mr. Browne undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. These shares are held by the Dan and Brenda Browne Living Trust. Mr. Browne is a Trustee of the Dan and Brenda Browne Living Trust. /s/ Gordon Ho, Attorney-in-Fact 2017-05-24